In recent clinical trials in patients with NAFLD [5,6,7,8,9,10,11], improving insulin sensitization using diabetes treating agents (i.e., a GLP-1 agonist) was shown to improve liver histology in NAFLD. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.